Bioventus Inc. 8-K

What Happened Bioventus Inc. filed an 8‑K on June 4, 2026 reporting the results of its 2026 Annual Meeting of Stockholders held June 3, 2026. A total of 75,279,174 shares of Class A and Class B common stock were present or represented by proxy (about 90.23% of outstanding shares as of the April 6, 2026 record date). All board nominees were elected to serve until the 2027 annual meeting, and stockholders ratified Grant Thornton LLP as the company’s independent registered public accounting firm for fiscal 2026.

Key Details

• Total shares present or represented: 75,279,174 (≈90.23% of outstanding shares; record date April 6, 2026).
• Directors elected (selected vote examples shown): William A. Hawkins (67,405,961 For; 1,128,994 Withheld); Ajay Dhankhar (68,459,149 For; 75,806 Withheld); Martin P. Sutter (61,710,650 For; 6,824,305 Withheld). All nominees were elected.
• Auditor ratification: Grant Thornton LLP ratified 75,228,481 For; 5,021 Against; 45,672 Abstentions; no broker non‑votes.
• The 8‑K was signed by Anthony D’Adamio, SVP & General Counsel, on June 4, 2026.

Why It Matters The filing confirms the board composition for the coming year and formalizes the company’s independent auditor for fiscal 2026—both governance items investors watch for oversight and financial reporting continuity. The high overall shareholder participation (~90%) indicates strong engagement; the relatively higher withheld votes for one director (Martin P. Sutter) is a specific voting outcome investors may note when monitoring board support and governance trends.